Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 3/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.78 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.71 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 14/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | FADS1 | O60427 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127962 | 0.88 | P2RX1 (1.00) | P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL16127831 | 0.85 | RXFP1 (0.76) | P2RX1PTGS1RXFP1MAPT | |
| SCHEMBL7814990 | 0.85 | P2RX1 (0.74) | P2RX1PTGS1RXFP1MAPT | |
| SCHEMBL9322590 | 0.85 | P2RX1 (0.73) | P2RX1P2RX4P2RX7PTGS1SLC2A1 | |
| SCHEMBL18327173 | 0.84 | MEN1 (0.79) | P2RX1P2RX4P2RX7FADS1 | |
| SCHEMBL31424184 | 0.84 | PTGS1 (1.00) | P2RX1PTGS1RXFP1MAPT | |
| SCHEMBL4031509 | 0.84 | PTGS1 (1.00) | P2RX1PTGS1RXFP1MAPT | |
| SCHEMBL5665824 | 0.84 | RXFP1 (0.88) | P2RX1PTGS1RXFP1 | |
| SCHEMBL3455896 | 0.84 | RXFP1 (0.88) | P2RX1P2RX4P2RX7PTGS1SLC2A1 | |
| SCHEMBL29392990 | 0.84 | PTGS1 (1.00) | P2RX1PTGS1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864360-B1 | TARGETED THERAPEUTICS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-09-06 | — | — | EP | claimed |
| US-20120232105-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING OSTEOCLAST GROWTH | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-09-13 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20220354872-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR RELIEVING PROGRESSION OF CHRONIC KIDNEY DISEASE OR PREVENTING THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2022-11-10 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| CN-104619727-B | Targeted therapy | 布里格姆及妇女医院股份有限公司 | 2019-04-05 | — | — | CN | disclosed |
| EP-3369747-A1 | TARGETED THERATPEUTICS | The Brigham and Women's Hospital, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180044396-A1 | COMPOUNDS AND METHODS FOR MODULATING PHARMACOKINETICS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9790264-B2 | Compounds and methods for modulating pharmacokinetics | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2864360-B1 | TARGETED THERAPEUTICS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-5905090-A | IMMUNOSUPPRESSANTS AND/OR ANTIINFLAMMATORIES | ITALFARMACO S.P.A. (IT) | 1999-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | P2RX1 4665/4885P2RX4 4750/4885P2RX7 4570/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | P2RX1 3481/4885P2RX4 3672/4885P2RX7 3565/4885 |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | P2RX1 3652/4885P2RX4 3484/4885P2RX7 3451/4885 |
| US-20120232105-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING OSTEOCLAST GROWTH | CCL11, ARG1, MSR1 | P2RX1 1248/4885P2RX4 1471/4885P2RX7 1191/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | P2RX1 4677/4885P2RX4 4746/4885P2RX7 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.